Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Govt OKs Action Plan on Drug Resistance
Cabinet ministers officially adopted an action plan on antimicrobial resistance on April 5, which calls for reducing the volume-based use of antimicrobials by 33% by 2020 from the 2013 level. After the day’s Cabinet meeting, Health Minister Yasuhisa Shiozaki told…
To read the full story
Related Article
- Govt Panel to Draw Up New AMR Action Plan for 2021 and Beyond
November 29, 2019
- Less than 40% of Public Aware that Antibacterials Are Ineffective Against Common Cold: Govt Survey
October 15, 2019
- MHLW Begins Drafting Manual on Proper Use of Antibiotics for Clinicians
December 21, 2016
- MRSA Infections Add 190 Billion Yen Annually to Medical Expenditure at DPC Hospitals: MHLW Study Group
July 25, 2016
- Govt Aims to Reduce Use of Antimicrobials by 33% by FY2020 as Part of Efforts to Fight Resistance
April 5, 2016
- Japan to Draw Up Action Plan on Drug Resistance: Health Minister
December 16, 2015
REGULATORY
- Avastin Price to Be Axed by 45% as G1 Rule Hits Originator Biologics
March 6, 2026
- Forxiga Slapped with 36% Price Cut on PMP Return in FY2026 Revision
March 6, 2026
- Japan Panel Clears Joenja, Dojolvi, Bayer MRI Contrast Agent
March 6, 2026
- Japan's Revised Drug Distribution Guidelines Take Effect
March 6, 2026
- Japan Drug Prices to Fall 4% in FY2026 Revision: Official Gazette
March 5, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…